Malignant pheochromocytoma and paraganglioma: Three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs

References

• Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58:802–4.
   PubMed Web of Science ®Google Scholar
• Adjallé R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009;41: 687–96.
   PubMed Web of Science ®Google Scholar
• Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14: 569–85.
   PubMed Web of Science ®Google Scholar
• Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, . Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006;1073:465–90.
   PubMed Web of Science ®Google Scholar
• Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, . Pheochromocytoma: Current approaches and future directions. Oncologist 2008;13:779–93.
   PubMed Web of Science ®Google Scholar
• Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. Lancet 2005;366(9486):665–75.
   PubMedGoogle Scholar
• Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, . Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423–36.
   PubMed Web of Science ®Google Scholar
• Disick GI, Palese MA. Extra-adrenal pheochromocytoma: Diagnosis and management. Curr Urol Rep 2007;8:83–8.
   PubMedGoogle Scholar
• Nomura K, Kimura H, Shimizu S, Kodama H, Okamoto T, Obara T, . Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy. J Clin Endocrinol Metab 2009;94:2850–6.
   PubMed Web of Science ®Google Scholar
• Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006;1073:374–82.
   PubMed Web of Science ®Google Scholar
• Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725–33.
   PubMed Web of Science ®Google Scholar
• Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008;52:334–40.
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, . Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986–91.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, . Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401–6.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Habra MA, Jiménez C. Malignant pheochromocytomas and paragangliomas: Molecular signaling pathways and emerging therapies. Horm Metab Res 2009;41: 680–6.
   PubMed Web of Science ®Google Scholar
• Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, . Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009;94:5–9.
   PubMed Web of Science ®Google Scholar
• Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ. Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 2009;27:460–3.
   PubMed Web of Science ®Google Scholar
• Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, . Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 2009;39:327–31.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, . Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26: 3403–10.
   PubMed Web of Science ®Google Scholar
• Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: What's new haven highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, Florida, USA. January 22–24, 2010 JOP. J Pancreas [Internet] 2010 Mar 5; 11:135–8.
   Google Scholar
• Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol 2010;37:662–79.
   PubMed Web of Science ®Google Scholar